Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Matthews, NC
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Matthews, NC
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Alexandria, VA
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches
Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches
Status: Enrolling
Updated:  12/31/1969
Grand Valley State University
mi
from
Grand Rapids, MI
Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches
Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches
Status: Enrolling
Updated: 12/31/1969
Grand Valley State University
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
21st Century Neurology
mi
from
Phoenix, AZ
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
21st Century Neurology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Tampa, FL
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
mi
from
Wesley Chapel, FL
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
mi
from
Wesley Chapel, FL
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Michigan Head Pain & Neurological Institute
mi
from
Ann Arbor, MI
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Michigan Head Pain & Neurological Institute
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Institute Inc.
mi
from
Minneapolis, MN
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Institute Inc.
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Healthy Perspectives Innovative Mental Health Services, PL
mi
from
Nashua, NH
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Healthy Perspectives Innovative Mental Health Services, PL
mi
from
Nashua, NH
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Pharmquest
mi
from
Greensboro, NC
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Pharmquest
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Foothill Family Clinic
mi
from
Salt Lake City, UT
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Foothill Family Clinic
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Health Research of Hampton Roads
mi
from
Newport News, VA
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Health Research of Hampton Roads
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated:  12/31/1969
Algemeen Ziekenhuis St Jan Brugge
mi
from
Brugge,
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status: Enrolling
Updated: 12/31/1969
Algemeen Ziekenhuis St Jan Brugge
mi
from
Brugge,
Click here to add this to my saved trials
Examining the Efficacy of Kiko Exercises on the Prevention of Migraine Headaches
Pilot Study Examining the Efficacy of Kiko Exercises on the Prevention of Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
Endwell Family Physicians
mi
from
Endwell, NY
Examining the Efficacy of Kiko Exercises on the Prevention of Migraine Headaches
Pilot Study Examining the Efficacy of Kiko Exercises on the Prevention of Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
Endwell Family Physicians
mi
from
Endwell, NY
Click here to add this to my saved trials
LSFG-SKIN, Laser Speckle Flowgraphy
LSFG-SKIN, Laser Speckle Flowgraphy
Status: Enrolling
Updated:  12/31/1969
University of Iowa Department of Ophthalmology
mi
from
Iowa City, IA
LSFG-SKIN, Laser Speckle Flowgraphy
LSFG-SKIN, Laser Speckle Flowgraphy
Status: Enrolling
Updated: 12/31/1969
University of Iowa Department of Ophthalmology
mi
from
Iowa City, IA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Simon-Williamson Clinic, P.C.
mi
from
Birmingham, AL
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Simon-Williamson Clinic, P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Achieve Clinical Research
mi
from
Birmingham, AL
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
East Valley Family Physicians, PC
mi
from
Chandler, AZ
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
East Valley Family Physicians, PC
mi
from
Chandler, AZ
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Desert Clinical Research
mi
from
Mesa, AZ
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Desert Clinical Research
mi
from
Mesa, AZ
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Central Phoenix Medical Clinic
mi
from
Phoenix, AZ
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Central Phoenix Medical Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Hope Clinical Reseach
mi
from
Canoga Park, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Hope Clinical Reseach
mi
from
Canoga Park, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Encino, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Sun Valley Research Center
mi
from
Imperial, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Sun Valley Research Center
mi
from
Imperial, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Irvine Center for Clinical Research
mi
from
Irvine, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Irvine Center for Clinical Research
mi
from
Irvine, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Synergy Clinical Research Centers
mi
from
Lemon Grove, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Synergy Clinical Research Centers
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Southland Neurologic
mi
from
Long Beach, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Southland Neurologic
mi
from
Long Beach, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Pacific Research Partners, LLC
mi
from
Oakland, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Pacific Research Partners, LLC
mi
from
Oakland, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Excell Research, Inc.
mi
from
Oceanside, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
mi
from
San Diego, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Artemis Institute for Clinical Research
mi
from
San Marcos, CA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Artemis Institute for Clinical Research
mi
from
San Marcos, CA
Click here to add this to my saved trials